Pharmacokinetics of monoclonal antibodies
JT Ryman, B Meibohm - CPT: pharmacometrics & systems …, 2017 - Wiley Online Library
JT Ryman, B Meibohm
CPT: pharmacometrics & systems pharmacology, 2017•Wiley Online LibraryMonoclonal antibodies (mAbs) have developed in the last two decades into the backbone of
pharmacotherapeutic interventions in a variety of indications, with currently more than 40
mAbs approved by the US Food and Drug Administration, and several dozens more in
clinical development. This tutorial will review major drug disposition processes relevant for
mAbs, and will highlight product‐specific and patient‐specific factors that modulate their
pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.
pharmacotherapeutic interventions in a variety of indications, with currently more than 40
mAbs approved by the US Food and Drug Administration, and several dozens more in
clinical development. This tutorial will review major drug disposition processes relevant for
mAbs, and will highlight product‐specific and patient‐specific factors that modulate their
pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product‐specific and patient‐specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.
Wiley Online Library